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Zinc isotopic compositions of breast cancer
tissue†
Fiona Larner,*ab Laura N. Woodley,c Sami Shousha,d Ashley Moyes,e
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Mark Rehka¨mperbf and R. Charles Coombesg
An early diagnostic biomarker for breast cancer is essential to improve outcome. High precision isotopic
analysis, originating in Earth sciences, can detect very small shifts in metal pathways. For the first time,
the natural intrinsic Zn isotopic compositions of various tissues in breast cancer patients and controls
were determined. Breast cancer tumours were found to have a significantly lighter Zn isotopic
composition than the blood, serum and healthy breast tissue in both groups. The Zn isotopic lightness in
tumours suggests that sulphur rich metallothionein dominates the isotopic selectivity of a breast tissue
cell, rather than Zn-specific proteins. This reveals a possible mechanism of Zn delivery to Zn-sequestering
vesicles by metallothionein, and is supported by a similar signature observed in the copper isotopic
compositions of one breast cancer patient. This change in intrinsic isotopic compositions due to cancer
has the potential to provide a novel early biomarker for breast cancer.
Introduction
Early diagnosis for breast cancer patients is critical to improve
outcome, and a biomarker that could detect the disease early
could be invaluable. High concentrations of zinc (Zn) have been
noted in breast cancer tissue for over a decade. The causative
changes in Zn metabolism at the molecular level have remained
elusive1–3 and traditional hospital-based measurements of metal
metabolism are insufficiently sensitive to provide a diagnostic
tool. New techniques for the high precision measurement of
natural isotopic compositions are far more sensitive and have
recently been used to illuminate previously undetectable trace
element biological pathways due to disease4–6 but not cancer.
Zinc is an essential trace element required by the human
body for more than 300 cellular processes7 but can be toxic in
excess and therefore requires a high level of regulation. Zinc
importer (Zip) and transporter (ZnT) proteins facilitate cellular
zinc homeostasis3 and several proteins within these families
appear disturbed in breast cancer cells. The anti-oxidant protein
metallothionein (MT) is also known to have a significant role in
cellular Znmetabolism, as well as for other essential metals such
as copper. Levels of MT are poorly regulated in breast cancer.2
Zinc concentrations have been reported to be significantly
higher in breast cancer tumours relative to healthy breast
tissue, and lower in blood serum and erythrocytes of breast
cancer patients compared to healthy controls.1,2,8,9 Increased
levels of Zips are present in breast cancer cells2 leading to
increased Zn uptake. Whilst some ZnT proteins promote Zn
eﬄux by sequestering excess cellular zinc into vesicles for later
use, extreme excess zinc triggers cell apoptosis in healthy cells.8
However the zinc transporter ZnT2 and MT are thought to be
overexpressed in malignant breast cancer cells,2,8 which protects
them from hyper accumulation of zinc and prevents tumour
cell death.
Natural stable isotope fractionation is one of the most sensitive
methods for exploring and quantifying environmental processes
past and present. The development of multiple collector induc-
tively coupled plasma mass spectrometry (MC-ICP-MS) has
facilitated stable isotope measurements for a far broader range
of elements than hitherto possible and provided important
information about Earth’s formation, the evolution of life and
mechanisms of climate change.10–12 Fractionation occurs when
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the light- or heavy-mass isotope(s) of an element are trans-
formed preferentially or more rapidly in a reaction, as a result
of mass dependent differences in the energy budget of the
process. This can happen, for example, due to changes in phase,
ligand coordination and redox state, or transport processes,
including biological uptake.13 The tightly controlled energy
requirements of biological systems mean the related isotopic
fractionation is typically significant, and facilitates a sensitive
monitor of metabolic change. In particular, zinc isotope fractio-
nation could differ when a cellular process is altered because of a
disease such as cancer; in principle it provides more insight than
concentration changes alone. Here we report the results of a pilot
investigation of Zn metabolism in breast cancer, by comparing
how the isotopic composition in different reservoirs changes with
malignancy.
Results & discussion
The Zn concentration and isotopic composition of blood and
blood serum of healthy controls and breast cancer patients
were determined, alongside a suite of 10 breast tissues, pre-
dominantly obtained from breast cancer patients (Fig. 1;
Table 1). As observed in other investigations,1,14 the Zn concen-
tration of tumours was found to be significantly higher than the
average values for healthy breast tissue reported in literature1,14
and found in this study. The isotopic composition is expressed
as the 66Zn/64Zn ratio. Variations in this composition due to
isotopic fractionation are small so are reported as the deviation,
@66Zn, in parts per thousand (%; eqn (1)) relative to a widely
available well-characterised source of zinc.
@66Zn (%) = [((66Zn/64Zn)sample/(
66Zn/64Zn)reference)  1]  1000
(1)
The samples of blood and of serum display limited isotopic
variation (d66Zn = 0.1 to + 0.3%). There is no systematic
diﬀerence between samples from healthy controls or breast
cancer patients. A haematoma sample from operation-induced
trauma is more negative (0.2%) however. The most negative
values (0.6 to 0.9%) are from breast cancer tissue. Healthy
tissue from breast cancer patients and one healthy control
show a Zn isotope composition lighter than blood and serum
(0.3 to 0.5%), but not as isotopically light as breast cancer
tissue. For one patient the healthy tissue was retrieved adjacent
to the tumour tissue and demonstrates a Zn isotope fractiona-
tion of approximately 0.5% and an isotopic diﬀerence of
around 0.9% between blood and tumour (Fig. 1). Therefore,
isotopically lighter zinc appears to be sequestered during
tumour formation.
Zinc metabolism in breast tissue is not fully understood,
however, it is thought that it is imported into breast cells via
Zips, buﬀered by MT and sequestered into intracellular vesicles
by ZnTs, in addition to other interactions which incorporate
Zn into functional roles (e.g. Zn-finger protein formation15).
Zinc isotopic fractionation can occur at any or all of these
transformative steps but the net eﬀect must be to produce
an isotopically light zinc pool. Ab initio modelling16,17 and
laboratory-based investigations18 of biological Zn interactions
indicate that, because of the stronger bonds formed, heavier
isotopes will preferentially bond to amino acids with harder
ligands, such as nitrogen and oxygen, whereas lighter isotopes
will be found with softer ligands such as sulfur.13 Both Zips and
ZnTs are noted for their numerous histidine (and therefore
nitrogen rich) residues.13 Therefore, they are unlikely candidates
for developing an isotopically light composition. Metallo-
thionein (MT) in contrast is S rich and capable of binding up
to seven Zn ions with its 20 cysteine residues. Metallothionein,
rather than a zinc-specific protein, therefore is most probably
responsible for the relatively light Zn isotope composition of
healthy tissue relative to blood, and of tumour tissue relative to
its healthy counterpart. The data indicate that the up-regulation of
Zips, ZnTs and MT in cancer cells magnifies the same isotopic
processes occurring in healthy cells, whereby the selectivity of the
MT overrides any heavy isotopic preference induced by the Zn
specific proteins.
This hypothesis is supported by the behaviour of copper (Cu)
isotopes in the same tissues (Fig. 2), which we have analysed in
a small number of samples (Table 1). Copper is not subject
to cell processes governed by Zn-specific proteins, however
the isotopic composition of Cu in the tumour relative to the
adjacent healthy tissue is isotopically lighter by 0.4% (Fig. 2).
Copper management is governed partly by copper-specific
proteins, (e.g. ATP7A, B, CTR1, ATOX119) as well as metallo-
thionein. There have been no reported up-regulation in
Cu-transporter proteins in breast cancer cells, therefore the
observed isotopic shift from healthy tissue to tumour is most
likely caused by binding of Cu to increased amounts of MT
present in the cell. This indicates that the magnitude of
isotopic fractionation of diﬀerent transition metals by this
protein is similar.
To preserve mass balance in the system, the sequestration of
isotopically light zinc into breast cancer cells requires an
isotopically heavy Zn pool to be present in the body as the
remnant of the original zinc source. Identification of this pool
could provide a new method of diagnosis. The diﬀerence in
Fig. 1 Variations in zinc isotope composition of breast cancer patients
and controls. Zinc isotope composition of blood (squares; n = 10), serum
(circles, n = 10), healthy breast tissue (hexagons, n = 4), haematoma
(diamond, n = 1) and tumour (stars, n = 5) samples from breast cancer
patients (yellow, dashed outline) and age-matched controls (blue, solid
outline). Tumours are significantly isotopically light compared to all other
tissues. Mean values are shown by horizontal lines in shaded regions.
Uncertainty is r0.2% (2SD), and is encompassed by shaded regions.
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isotope composition of Zn caused by the tumour is not detectable
in the blood or serum of cancer patients relative to healthy
controls (Fig. 1). The d66Zn value of blood has been shown
to vary by 0.2% due to diet,20 therefore the normalization of
each individual’s serum Zn isotope composition to the blood
composition can be used to remove scatter introduced by dietary
influence. This, however, does not increase resolution between
the two groups, and confirms that the simple measurement of
these easily accessible sample types cannot be used to identify
the diagnostic heavy Zn isotope pool if analysed in bulk form.
The mixing of two reservoirs can change the isotopic
composition of the resultant pool to varying degrees and is
represented by the haematoma sample (blood pool with healthy
tissue cells) analysed (Fig. 1). This sample has a Zn isotopic
composition between that of blood and the healthy tissue
samples, representing the mixing of the two pools in this
sample, whereby the contribution of the healthy tissue cells is
large enough to perturb the intrinsic composition of the blood.
Using mixing calculations (see ESI†) and the average zinc
isotope values and concentrations of the blood and tumours
measured here, it can be shown that the lack of signal in the
blood from tumour growth is to be expected. The background
zinc pool in the blood, typicallyB5 L of 100 mM Zn, is too large
and acts as a buﬀer to the small reservoir of isotopically heavy
excreted zinc originating from the tumour; for example, growth
of a 1 g tumour would perturb the Zn isotope composition of
blood (D66Zn) by o0.0005%.
Although bulk blood does not reveal an isotopic eﬀect it
would be important to be able to identify and isolate a more
discrete isotopically heavy pool of Zn that is residual to the light
tumour-sequestered Zn. It could provide an important early
biomarker for the disease. The mechanism resulting in the
expulsion of isotopically heavy Zn from the tumour cells is key
to finding the appropriate compartment containing the bio-
marker and, for example, could be in white blood cells or a
specific protein size fraction from blood. The mass balance of
Table 1 Summary of patient information, zinc and copper isotope compositions and concentration data for individuals and standard materialsa
Sample Gender
Grade
(% tumour
cellularity) Type [Zn] mM
@66ZnIRMM3702
(%) 2s (%) n (m) [Cu] mM
@65CuERM-AE633
(%) 2s n (m)
Reference materials
London Zn Pure solution — 0.19 0.10 60 (4)
IRMM 3702 Zn Pure solution — 0.00 0.10 6 (4)
Romil Cu Pure solution — 0.17 0.16 62(4)
BCR-639 Serum 40.9 3.06 0.20 8 (5) 16.0 0.53 0.06 1
Controls
Zn001HC F Blood 101 0.07 0.15 1 14.4 0.08 0.06 1
Serum 11.0 0.15 0.11 2(2) 12.8 0.57 0.16 1
Zn002HC F Blood 84.9 0.09 0.10 2(2) 10.8 0.78 0.16 1
Zn003HC F Blood 90.8 0.15 0.10 2(2) 12.3 0.93 0.16 1
Serum 14.6 0.28 0.10 1 15.8 0.43 0.16 1
Zn004HC F Blood 93.3 0.07 0.10 2(2) 12.8 1.03 0.06 1
Serum 15.3 0.04 0.08 2(2) 18.7 0.52 0.16 1
Zn007HC M Blood 96.1 0.14 0.09 1
Serum 13.0 0.13 0.11 1
Zn008HC M Blood 76.9 0.11 0.12 1
Serum 11.5 0.23 0.11 1
Zn014HC F Healthy tissue 98.8 0.31 0.06 1
Breast cancer
Zn001 F 2 Blood 58.1 0.20 0.09 1
Serum 16.0 0.25 0.11 1
Haematoma 57.6 0.16 0.12 1
Zn002 F 2 Blood 61.1 0.13 0.10 3(3) 10.4 0.74 0.16 1
Serum 13.9 0.22 0.10 2(2) 15.3 0.60 0.16 1
Zn003 M 2 (80) Blood 70.8 0.01 0.10 2(2) 11.1 0.08 0.06 1
Serum 13.4 0.04 0.10 2(2) 11.9 0.96 0.12 1
Tumour 64.3 0.77 0.08 2(2)
Zn005 F 3 Blood 95.8 0.05 0.10 1 14.6 0.07 0.06 1
Serum 15.3 0.20 0.15 1 15.7 0.74 0.06 1
Zn006 M 1 (90) Blood 87.5 0.09 0.14 1 12.6 0.62 0.06 1
Serum 13.1 0.03 0.10 2(2) 14.0 0.45 0.06 1
Tumour 156 0.90 0.06 1(2) 10.2 0.48 0.06 1
Healthy tissue 33.5 0.39 0.10 1 2.6 0.83 0.06 1
Zn009 F 3 (490) Tumour 153 0.78 0.09 1
Zn010 F 2 (50) Tumour 65.0 0.86 0.09 1
Zn011 F 2 (90) Tumour 151 0.56 0.09 1
Zn012 F 2 Healthy tissue 23.2 0.36 0.06 1
Zn013 F 2 Healthy tissue 16.2 0.49 0.06 1
a For isotope compositions, n = number of full procedural separations, m = number of analytical sessions on MC-ICP-MS. Italicized concentrations
determined from MC-ICP-MS data.
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Zn between the tumour and this unknown heavy pool is
unconstrained at present. However, mixing calculations
(eqn (S1)–(S7), ESI†) predict that the residual isotopic signature
of the measured heavy pool will be sufficiently different to
distinguish between breast cancer patients and healthy controls
if the unknown heavy pool represents only 30% or less of the
total Zn in the reservoir from which it is extracted (Fig. 3; see
ESI† for more detailed analysis). Given that tumours are
enriched in Zn this may be possible.
The continuous replenishment of bodily Zn from the diet
could have a significant eﬀect on any relationship between
isotopic composition and disease severity. This remains to be
properly explored. This pilot data can be linked to up-regulation
of particular proteins in breast cancer cells, however, the
presence of other cells in cancer, such as those associated with
inflammation,21,22 and their eﬀect onmetal metabolismmay also
have a mechanistic role which results in the observed isotopic
changes. Additional studies are needed to detect any isotopically
heavy pool and the degree to which this might not only identify
cancer and shed light on specific Zn transfer mechanisms but
also indicate the progression of the disease.
Conclusion
Mechanistic changes in zinc metabolism on tumour formation
in breast cancer are reflected in the change of natural intrinsic
zinc isotopic composition of breast tissue. Whilst the causes
are not certain, this observation implicates the potential use of
high precision isotopic analysis to develop a new, early bio-
marker for breast cancer.
Experimental
Sample collection
This study was approved by the Tissue Management Committee
of the Imperial College NHS Healthcare Tissue Bank. Informed
patient consent was obtained before the collection of samples.
Sample collection was performed at Charing Cross Hospital,
Imperial College NHS Trust, London UK. Samples were collected
in clean Teflon vials from breast cancer patients (blood, serum,
tumour, healthy tissue, haematoma) and age matched controls
(blood, serum). Tumour and haematoma samples were taken
using precleaned ceramic knives, with the exception of three
previously collected tumor samples supplied directly from the
tissue bank in plastic vials.
Sample preparation
Samples were prepared for Zn and Cu isotopic composition and
concentration analysis in Class 10 laminar flow hoods either in
the MAGIC Clean Room Laboratory, Imperial College London
or at the Clean Laboratory Suite at the University of Oxford.
Quartz distilled acids diluted with 18 MO cm H2O (Millipore)
if necessary were used throughout for sample preparation.
Samples (0.25–0.5 ml or o0.5 g) were microwave digested in
a 3 + 2 mixture of 15 M HNO3 + 30% H2O2 (vol/vol) ramping
over 90 min to 210 1C, 250 psi.
Concentration and isotopic analysis
Zinc and copper concentrations were determined by ICP-AES
and ICP-MS at the Natural History Museum, London (Table 1).
The Zn concentrations were used to allow accurate double
spiking prior to Zn isolation from the sample matrix via anion
exchange chromatography.23,24 Isotope analyses were performed
using the Nu Instruments Nu Plasma HR MC-ICP-MS at the
appropriate resolution mode (Cu: low, Zn: medium) with either
an Aridus (Cetac, ICL) or a DSN (Nu Instruments, Oxford)
desolvating sample introduction system. Isotope measurements
were performed as previously described.25,26 A reference solution
was measured at least twice either side of sample analyses to
monitor and allow accurate correction of changes in instru-
mental mass bias, as described previously.23,24,26 The data
retrieved from the MC-ICP-MS measurements were used to
calculate the diﬀerence in isotope composition (d66Zn or d65Cu)
Fig. 2 Zinc and copper isotope compositions of various tissues for one
breast cancer patient. The combined Zn and Cu isotopic compositions of
tumour, healthy tissue, serum and blood of one patient separates the
tissues into distinct areas, showing isotopic processes between various
body pools. The red arrow highlights similar isotopic behaviour for copper
and zinc on the formation of tumour tissue. Uncertainty isr0.2% (2SD).
Fig. 3 The predicted zinc pool required for diagnosis using natural iso-
topic Zn fractionation. The modelled change in Zn isotope composition
(D66Znmix) of a diagnostic pool (e.g. white blood cells) due to the eﬀect of
the size of the tumour Zn pool (40% dotted line, 60% dashed line, 80%
solid line) on the residual diagnostic pool. An analytical precision of 0.20%
means that at least 5% of the sampled pool must consist of the unknown
heavy Zn pool (Fout) to provide a diagnosis.
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of a sample (sam) relative to the average of the bracketing
standard solutions (std; equation 1), Cu by exponential normali-
zation with nickel24 and Zn by double spike deconvolution.23
Isotopic values are reported relative to the well-characterised
materials IRMM-3702 (Zn) and ERM-AE633 (Cu).27 The Zn and
Cu blank contribution were monitored to ensure results were not
influenced by background levels and was typically o1% of the
total sample Zn or Cu respectively. The reproducibility of the
methods were monitored by (i) repeat measurements of an in
house standard alongside samples, (ii) the processing and
measurement of the same samples through the whole method
twice, and (iii) the measurement of a matrix matched standard
material, BCR-639 Human serum, with multiple batches of
samples (Table 1). The external reproducibility of the in house
standard is 0.10% (2SD) and the vast majority of the samples
are within this uncertainty, and all are within the reproducibility
of the matrix matched standard.
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